Drug intelligence / Profile preview

SRD-001 (Sardocor)

Development stage: Preclinical
Lead developer: Sardocor
Modality: Small Molecules
Administration: Intracoronary Infusion

Overview

SRD-001 is a preclinical small-molecule drug candidate being developed by Sardocor for the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). It acts as a modulator of the Sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a), an enzyme critical for calcium homeostasis in cardiomyocytes. In HFrEF, SERCA2a activity is typically downregulated, leading to impaired calcium reuptake into the sarcoplasmic reticulum and reduced cardiac contractility. By enhancing SERCA2a function, SRD-001 aims to restore efficient calcium cycling, thereby improving heart function and contractile performance.

Targets

SERCA2

Beyond the preview

Go deeper on SRD-001 (Sardocor).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRD-001 (Sardocor).

Explore the full profile